MicroRNAs as Diagnostic Biomarkers and Predictors of Antidepressant Response in Major Depressive Disorder: A Systematic Review

被引:3
|
作者
Carneiro, Beatriz A. [1 ]
Guerreiro-Costa, Livia N. Franco [2 ]
Lins-Silva, Daniel [1 ]
Guimaraes, Daniela Faria [1 ]
Souza, Lucca S. [1 ]
Leal, Gustavo C. [3 ]
Caliman-Fontes, Ana Teresa [3 ]
Beanes, Graziele [1 ]
Costa, Ryan Dos S. [4 ]
Quarantini, Lucas C. [5 ]
机构
[1] Univ Fed Bahia, Lab Neuropsicofarmacol, Serv Psiquiatria, Hosp Univ Prof Edgard Santos,Med, Salvador, Brazil
[2] Univ Fed Bahia, Med, Salvador, Brazil
[3] Univ Fed Bahia, Fac Med Bahia, Programa Posgrad Med & Saude, Med, Salvador, Brazil
[4] Univ Fed Bahia, Inst Ciencias Saude, Lab Imunofarmacol & Biol Mol, Med, Salvador, Brazil
[5] Univ Fed Bahia, Psychiat, Salvador, Brazil
关键词
micrornas; biomarkers; antidepressive agents; major; depressive disorder; MESSENGER-RNA; EXPRESSION; BRAIN; PLASTICITY; DULOXETINE; MIR-1202; GENE;
D O I
10.7759/cureus.56910
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite the hardships of major depressive disorder (MDD), biomarkers for the diagnosis and pharmacological management of this condition are lacking. MicroRNAs are epigenetic mechanisms that could provide promising MDD biomarkers. Our aim was to summarize the findings and provide validation for the selection and use of specific microRNAs as biomarkers in the diagnosis and treatment of MDD. A systematic review was conducted using the PubMed/Medline, Cochrane, PsycINFO, Embase, and LILACS databases from March 2022 to November 2023, with clusters of terms based on "microRNA" and "antidepressant". Studies involving human subjects, animal models, and cell cultures were included, whereas those that evaluated herbal medicines, non -pharmacological therapies, or epigenetic mechanisms other than miRNA were excluded. The review revealed differences in the expression of various microRNAs when considering the time of assessment (before or after antidepressant treatment) and the population studied. However, due to the heterogeneity of the microRNAs investigated, the limited size of the samples, and the wide variety of antidepressants used, few conclusions could be made. Despite the observed heterogeneity, the following microRNAs were determined to be important factors in MDD and the antidepressant response: mir-1202, mir-135, mir-124, and mir-16. The findings indicate the potential for the use of microRNAs as biomarkers for the diagnosis and treatment of MDD; however, more homogeneous studies are needed.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] Biomarkers as predictors of treatment response to tricyclic antidepressants in major depressive disorder: A systematic review
    Hark, Sophie E. ter
    Vos, Cornelis F.
    Aarnoutse, Rob E.
    Schene, Aart H.
    Coenen, Marieke J. H.
    Janzing, Joost G. E.
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2022, 150 : 202 - 213
  • [2] Growth Factors as Biomarkers of Major Depressive Disorder and Potential Predictors of Antidepressant Drug Response
    Halaris, Angelos
    Clark-Raymond, Anne
    Meresh, Edwin
    Sharma, Aparna
    Kang, Robin
    Hage, Brandon
    Morrissey, Kathryn
    Fareed, Jawed
    Pandey, Ghanshyam
    [J]. NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S502 - S503
  • [3] A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder
    Perlman, Kelly
    Benrimoh, David
    Israel, Sonia
    Rollins, Colleen
    Brown, Eleanor
    Tunteng, Jingla-Fri
    You, Raymond
    You, Eunice
    Tanguay-Sela, Myriam
    Snook, Emily
    Miresco, Marc
    Berlim, Marcelo T.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2019, 243 : 503 - 515
  • [4] A Systematic Review of Circulatory microRNAs in Major Depressive Disorder: Potential Biomarkers for Disease Prognosis
    Rasheed, Madiha
    Asghar, Rabia
    Firdoos, Sundas
    Ahmad, Nadeem
    Nazir, Amina
    Ullah, Kakar Mohib
    Li, Noumin
    Zhuang, Fengyuan
    Chen, Zixuan
    Deng, Yulin
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
  • [5] Cerebral Blood Perfusion Predictors of Antidepressant Response in Major Depressive Disorder
    Cooper, Crystal
    Fatt, Cherise Chin
    Fonzo, Gregory
    Jha, Manish
    Grannemann, Bruce
    Aslan, Sina
    Almeida, Jorge
    Deckersbach, Thilo
    Fava, Maurizio
    Kurian, Benji
    McGrath, Patrick
    McInnis, Melvin
    Parsey, Ramin
    Weissman, Myrna
    Phillips, Mary
    Lu, Hanzhang
    Etkin, Amit
    Trivedi, Madhukar
    [J]. BIOLOGICAL PSYCHIATRY, 2018, 83 (09) : S399 - S399
  • [6] Uncovering the Roles of MicroRNAs in Major Depressive Disorder: From Candidate Diagnostic Biomarkers to Treatment Response Indicators
    Homorogan, Claudia
    Nitusca, Diana
    Seclaman, Edward
    Enatescu, Virgil
    Marian, Catalin
    [J]. LIFE-BASEL, 2021, 11 (10):
  • [7] Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder
    Hunter, Aimee M.
    Muthen, Bengt O.
    Cook, Ian A.
    Leuchter, Andrew F.
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2010, 44 (02) : 90 - 98
  • [8] Biomarker Predictors of Antidepressant Response to Dorsomedial Prefrontal rTMS in Major Depressive Disorder
    Giacobbe, Peter
    Downar, Jonathan
    McAndrews, Mary P.
    Salomons, Tim
    Flint, Alastair
    Kennedy, Sidney H.
    [J]. BIOLOGICAL PSYCHIATRY, 2012, 71 (08) : 282S - 282S
  • [9] Amygdala biomarkers of treatment response in major depressive disorder: An fMRI systematic review of SSRI antidepressants
    Tassone, Vanessa K.
    Nezhad, Fatemeh Gholamali
    Demchenko, Ilya
    Rueda, Alice
    Bhat, Venkat
    [J]. PSYCHIATRY RESEARCH-NEUROIMAGING, 2024, 338
  • [10] Systematic review of pindolol augmentation of serotonergic antidepressant treatment for major depressive disorder
    Whale, R
    Terao, T
    Cowen, PJ
    Geddes, J
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S420 - S420